Many studies demonstrate favorable effects of GH replacement therapy in adults with GH deficiency (8, 9), and of normalization of GH and IGF-1 levels in acromegaly (10), on cardiovascular risk factors, but the presented data suggest that there may be an optimal target level of IGF-1. Here, IGF1 is linked to acromegaly.